PMID- 20708812
OWN - NLM
STAT- MEDLINE
DCOM- 20110202
LR  - 20221207
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 90
IP  - 2
DP  - 2010 Nov
TI  - DPP-4 inhibitors: what may be the clinical differentiators?
PG  - 131-40
LID - 10.1016/j.diabres.2010.07.006 [doi]
AB  - Attenuation of the prandial incretin effect, mediated by glucagon-like peptide-1 
      (GLP-1) and glucose-dependent insulinotropic peptide (GIP), contributes to 
      hyperglycemia in type 2 diabetes mellitus (T2DM). Since the launch of sitagliptin 
      in 2006, a compelling body of evidence has accumulated showing that dipeptidyl 
      peptidase-4 (DPP-4) inhibitors, which augment endogenous GLP-1 and GIP levels, 
      represent an important advance in the management of T2DM. Currently, three DPP-4 
      inhibitors - sitagliptin, vildagliptin and saxagliptin - have been approved in 
      various countries worldwide. Several other DPP-4 inhibitors, including 
      linagliptin and alogliptin, are currently in clinical development. As 
      understanding of, and experience with, the growing number of DPP-4 inhibitors 
      broadens, increasing evidence suggests that the class may offer advantages over 
      other antidiabetic drugs in particular patient populations. The expanding 
      evidence base also suggests that certain differences between DPP-4 inhibitors may 
      prove to be clinically significant. This therapeutic diversity should help 
      clinicians tailor treatment to the individual patient, thereby increasing the 
      proportion that safely attain target HbA(1c) levels, and reducing morbidity and 
      mortality. This review offers an overview of DPP-4 inhibitors in T2DM and 
      suggests some characteristics that may provide clinically relevant 
      differentiators within this class.
CI  - Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
FAU - Gerich, John
AU  - Gerich J
AD  - University of Rochester School of Medicine, Rochester, NY 14642, USA. 
      john_gerich@urmc.rochester.edu
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100813
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptides)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Nitriles)
RN  - 0 (Piperidines)
RN  - 0 (Purines)
RN  - 0 (Pyrazines)
RN  - 0 (Pyrrolidines)
RN  - 0 (Quinazolines)
RN  - 0 (Triazoles)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - 56HH86ZVCT (Uracil)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9GB927LAJW (saxagliptin)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
RN  - I6B4B2U96P (Vildagliptin)
RN  - JHC049LO86 (alogliptin)
RN  - PJY633525U (Adamantane)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
CIN - Diabetes Res Clin Pract. 2011 Jul;93(1):e3-4. PMID: 21459471
MH  - Adamantane/analogs & derivatives/therapeutic use
MH  - Blood Glucose/drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptides/therapeutic use
MH  - Dipeptidyl Peptidase 4/drug effects
MH  - Dipeptidyl-Peptidase IV Inhibitors/classification/*therapeutic use
MH  - Energy Intake
MH  - Gastric Emptying/drug effects
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - Glycated Hemoglobin/*drug effects/metabolism
MH  - Humans
MH  - Hyperglycemia/prevention & control
MH  - Hypoglycemic Agents/therapeutic use
MH  - Incretins/metabolism/physiology
MH  - Intestinal Mucosa/drug effects/physiology/physiopathology
MH  - Linagliptin
MH  - Neurons/drug effects/physiology
MH  - Nitriles/therapeutic use
MH  - Piperidines/therapeutic use
MH  - Purines/therapeutic use
MH  - Pyrazines/therapeutic use
MH  - Pyrrolidines/therapeutic use
MH  - Quinazolines/therapeutic use
MH  - Sitagliptin Phosphate
MH  - Triazoles/therapeutic use
MH  - Uracil/analogs & derivatives/therapeutic use
MH  - Vildagliptin
EDAT- 2010/08/17 06:00
MHDA- 2011/02/03 06:00
CRDT- 2010/08/17 06:00
PHST- 2010/05/14 00:00 [received]
PHST- 2010/07/12 00:00 [revised]
PHST- 2010/07/13 00:00 [accepted]
PHST- 2010/08/17 06:00 [entrez]
PHST- 2010/08/17 06:00 [pubmed]
PHST- 2011/02/03 06:00 [medline]
AID - S0168-8227(10)00361-X [pii]
AID - 10.1016/j.diabres.2010.07.006 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2010 Nov;90(2):131-40. doi: 
      10.1016/j.diabres.2010.07.006. Epub 2010 Aug 13.